A case report: The first show phenomenon in the treatment of spinal cord injury with Regentime procedure using autologous bone marrow‐derived stem cells

Key Clinical Message Promising outcomes are shown in this case report using the Regentime procedure and autologous stem cells to treat spinal cord injury. The observed “First Show Phenomenon” provides valuable insights into the therapy's potential for spinal cord injury. Abstract This case report demonstrates “the first show phenomenon” following Regentime stem cell therapy applied to a spinal cord injury patient. A 40‐year‐old gentleman sustained a ballistic injury at the level of T9, resulting in complete bilateral motor and sensory loss from T9 and below. He was treated with autologous bone marrow‐derived mononuclear stem cells injected into his spinal canal 2.5 years after his injury. Follow‐up during the first‐week posttransplantation showed early symptom improvement termed “the first show phenomenon.” He regained sensation to light touch in his lower limbs by the end of week 1 and reported no serious implications or complications

The Regentime stem cell procedure, successful treatment for a Charcot–Marie–Tooth disease case

Key Clinical Message This report highlights the successful treatment of a Charcot–Marie–Tooth disease case using the Regentime stem cell procedure, suggesting its potential as a promising therapeutic approach for patients suffering from this challenging condition